List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3410961/publications.pdf Version: 2024-02-01



IINRIN XII

#	Article	IF	CITATIONS
1	Striatal oxidative damages and neuroinflammation correlate with progression and survival of Lewy body and Alzheimer diseases. Neural Regeneration Research, 2022, 17, 867.	3.0	8
2	Dopamine D3 Receptor in Parkinson Disease: A Prognosis Biomarker and an Intervention Target. Current Topics in Behavioral Neurosciences, 2022, , .	1.7	0
3	Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents. Biomedicines, 2021, 9, 565.	3.2	18
4	Neuropathic Pain: Biomolecular Intervention and Imaging via Targeting Microglia Activation. Biomolecules, 2021, 11, 1343.	4.0	18
5	Dopamine D1Â+ÂD3 receptor density may correlate with parkinson disease clinical features. Annals of Clinical and Translational Neurology, 2021, 8, 224-237.	3.7	12
6	The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases. Journal of Neurochemistry, 2020, 152, 235-251.	3.9	17
7	Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?. Ageing Research Reviews, 2020, 57, 100994.	10.9	57
8	Radiolabeled 6-(2, 3-Dichlorophenyl)-N4-methylpyrimidine-2, 4-diamine (TH287): A Potential Radiotracer for Measuring and Imaging MTH1. International Journal of Molecular Sciences, 2020, 21, 8860.	4.1	3
9	Microglia Implicated in Tauopathy in the Striatum of Neurodegenerative Disease Patients from Genotype to Phenotype. International Journal of Molecular Sciences, 2020, 21, 6047.	4.1	8
10	<sup>64</sup> Cu-ATSM Positron Emission Tomography/Magnetic Resonance Imaging of Hypoxia in Human Atherosclerosis. Circulation: Cardiovascular Imaging, 2020, 13, e009791.	2.6	13
11	Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains. Annals of Clinical and Translational Neurology, 2019, 6, 1423-1434.	3.7	22
12	Neuroinflammation and Myelin Status in Alzheimer's Disease, Parkinson's Disease, and Normal Aging Brains: A Small Sample Study. Parkinson's Disease, 2019, 2019, 1-12.	1.1	23
13	ICâ€Pâ€166: TAU PET IMAGING IN LGI1 ENCEPHALITIS: DECIPHERING THE CONTRIBUTORS TO COGNITIVE IMPAIRMENT IN AUTOIMMUNE ENCEPHALITIS. Alzheimer's and Dementia, 2019, 15, P131.	0.8	0
14	Amino Acid Uptake Measured by [18F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas. Theranostics, 2018, 8, 2107-2116.	10.0	7
15	Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer. Nuclear Medicine and Biology, 2018, 66, 26-31.	0.6	29
16	The role of beta-arrestin2 in shaping fMRI BOLD responses to dopaminergic stimulation. Psychopharmacology, 2017, 234, 2019-2030.	3.1	4
17	Nd-Fe-B permanent magnet generator and voltage stabilizing control technology for vehicles. Advances in Mechanical Engineering, 2016, 8, 168781401666963.	1.6	4
18	PET imaging of in vivo caspase-3/7 activity following myocardial ischemia-reperfusion injury with the radiolabeled isatin sulfonamide analogue [(18)F]WC-4-116. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 110-9.	1.0	11

#	Article	IF	CITATIONS
19	Absorbed radiation dosimetry of the D-specific PET radioligand [F]FluorTriopride estimated using rodent and nonhuman primate. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 301-309.	1.0	6
20	Synthesis, pharmacological evaluation and molecular modeling studies of triazole containing dopamine D3 receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 519-523.	2.2	15
21	Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils. Journal of Medicinal Chemistry, 2015, 58, 6002-6017.	6.4	92
22	Sigma-2 receptor binding is decreased in female, but not male, APP/PS1 mice. Biochemical and Biophysical Research Communications, 2015, 460, 439-445.	2.1	16
23	Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity. PLoS ONE, 2014, 9, e111899.	2.5	151
24	Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. Bioorganic and Medicinal Chemistry, 2014, 22, 1700-1707.	3.0	64
25	Using SV119 old Nanocage Conjugates to Eradicate Cancer Stem Cells Through a Combination of Photothermal and Chemo Therapies. Advanced Healthcare Materials, 2014, 3, 1283-1291.	7.6	69
26	Epigenetic Priming of Memory Updating during Reconsolidation to Attenuate Remote Fear Memories. Cell, 2014, 156, 261-276.	28.9	318
27	Development of a PET radiotracer for non-invasive imaging of the reactive oxygen species, superoxide, in vivo. Organic and Biomolecular Chemistry, 2014, 12, 4421-4431.	2.8	74
28	Cross-Inhibition of NMBR and GRPR Signaling Maintains Normal Histaminergic Itch Transmission. Journal of Neuroscience, 2014, 34, 12402-12414.	3.6	55
29	Synthesis and Structure–Activity Relationship Studies of Conformationally Flexible Tetrahydroisoquinolinyl Triazole Carboxamide and Triazole Substituted Benzamide Analogues as σ <sub>2</sub> Receptor Ligands. Journal of Medicinal Chemistry, 2014, 57, 4239-4251.	6.4	33
30	Functional assays to define agonists and antagonists of the sigma-2 receptor. Analytical Biochemistry, 2014, 448, 68-74.	2.4	35
31	Positron emission tomography imaging of dopamine D2 receptors using a highly selective radiolabeled D2 receptor partial agonist. NeuroImage, 2013, 71, 168-174.	4.2	10
32	Regulation of dopamine presynaptic markers and receptors in the striatum of DJ-1 and Pink1 knockout rats. Neuroscience Letters, 2013, 557, 123-128.	2.1	25
33	Regulation of dopamine D3 receptor in the striatal regions and substantia nigra in diffuse Lewy body disease. Neuroscience, 2013, 248, 112-126.	2.3	25
34	Binding of the Radioligand SIL23 to α-Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent. PLoS ONE, 2013, 8, e55031.	2.5	97
35	Quantitative Receptor-Based Imaging of Tumor Proliferation with the Sigma-2 Ligand [18F]ISO-1. PLoS ONE, 2013, 8, e74188.	2.5	41
36	Use of Multifunctional Sigma-2 Receptor Ligand Conjugates to Trigger Cancer-Selective Cell Death Signaling. Cancer Research, 2012, 72, 201-209.	0.9	41

#	Article	IF	CITATIONS
37	SV119-gold nanocage conjugates: a new platform for targeting cancer cellsvia sigma-2 receptors. Nanoscale, 2012, 4, 421-424.	5.6	45
38	Synthesis and evaluation of in vitro bioactivity for vesicular acetylcholine transporter inhibitors containing two carbonyl groups. Bioorganic and Medicinal Chemistry, 2012, 20, 4422-4429.	3.0	16
39	Abstract 356: Photoacoustic imaging of pancreatic cancer proliferation via sigma-2 receptor/PGRMC1-eYFP. Cancer Research, 2012, 72, 356-356.	0.9	1
40	No Differential Regulation of Dopamine Transporter (DAT) and Vesicular Monoamine Transporter 2 (VMAT2) Binding in a Primate Model of Parkinson Disease. PLoS ONE, 2012, 7, e31439.	2.5	28
41	Dopamine D1, D2, D3 Receptors, Vesicular Monoamine Transporter Type-2 (VMAT2) and Dopamine Transporter (DAT) Densities in Aged Human Brain. PLoS ONE, 2012, 7, e49483.	2.5	62
42	Abstract 5690: Validating sigma-2 receptor ligand as a novel tumor-targeted drug delivery agent for treating ovarian cancer. , 2012, , .		0
43	Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nature Communications, 2011, 2, 380.	12.8	277
44	Synthesis and in Vitro Biological Evaluation of Carbonyl Group-Containing Analogues for Ïf <sub>1</sub> Receptors. Journal of Medicinal Chemistry, 2011, 54, 5362-5372.	6.4	15
45	Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain. Nuclear Medicine and Biology, 2011, 38, 725-739.	0.6	14
46	Characterization and Evaluation of Two Novel Fluorescent Sigma-2 Receptor Ligands as Proliferation Probes. Molecular Imaging, 2011, 10, 7290.2011.00009.	1.4	37
47	Sleep deprivation differentially affects dopamine receptor subtypes in mouse striatum. NeuroReport, 2011, 22, 489-493.	1.2	36
48	Synthesis and inÂvitro evaluation of new analogues as inhibitors for phosphodiesterase 10A. European Journal of Medicinal Chemistry, 2011, 46, 3986-3995.	5.5	8
49	PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. Experimental Neurology, 2011, 232, 333-338.	4.1	35
50	Synthesis and Pharmacological Evaluation of Fluorine-Containing D <sub>3</sub> Dopamine Receptor Ligands. Journal of Medicinal Chemistry, 2011, 54, 1555-1564.	6.4	42
51	Endogenous dopamine (DA) competes with the binding of a radiolabeled D <sub>3</sub> receptor partial agonist in vivo: A positron emission tomography study. Synapse, 2011, 65, 724-732.	1.2	39
52	Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. Bioorganic and Medicinal Chemistry, 2011, 19, 1666-1673.	3.0	55
53	Synthesis and characterization of selective dopamine D2 receptor ligands using aripiprazole as the lead compound. Bioorganic and Medicinal Chemistry, 2011, 19, 3502-3511.	3.0	43
54	Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes. Molecular Imaging, 2011, 10, 420-33.	1.4	22

#	Article	IF	CITATIONS
55	Radiosynthesis and biological evaluation of a promising Ïf2-receptor ligand radiolabeled with fluorine-18 or iodine-125 as a PET/SPECT probe for imaging breast cancer. Applied Radiation and Isotopes, 2010, 68, 2268-2273.	1.5	28
56	Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. Bioorganic and Medicinal Chemistry, 2010, 18, 5291-5300.	3.0	20
57	[ <sup>3</sup> H]4â€{dimethylamino)â€ <i>N</i> â€{4â€{4â€{2â€methoxyphenyl)piperazinâ€1â€yl) butyl)benza selective radioligand for dopamine D <sub>3</sub> receptors. II. Quantitative analysis of dopamine D <sub>3</sub> and D <sub>2</sub> receptor density ratio in the caudateâ€putamen. Synapse, 2010, 64, 449-459.	amide: A 1.2	34
58	The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Molecular Cancer, 2010, 9, 298.	19.2	70
59	Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. Nuclear Medicine and Biology, 2010, 37, 509-516.	0.6	48
60	Abstract 1054: Identification of progesterone receptor membrane component-1 as the putative sigma-2 receptor. , 2010, , .		0
61	[ <sup>3</sup> H]4â€{Dimethylamino)â€ <i>N</i> â€{4â€{4â€{2â€methoxyphenyl)piperazin―1â€yl)butyl]benz selective radioligand for dopamine D <sub>3</sub> receptors. I. In vitro characterization. Synapse, 2009, 63, 717-728.	amide, a 1.2	27
62	New N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs as σ2 receptor ligands: Synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents. Bioorganic and Medicinal Chemistry, 2009, 17, 1222-1231.	3.0	40
63	Synthesis and in Vitro and in Vivo Evaluation of <sup>18</sup> F-Labeled Positron Emission Tomography (PET) Ligands for Imaging the Vesicular Acetylcholine Transporter. Journal of Medicinal Chemistry, 2009, 52, 1358-1369.	6.4	48
64	Subcellular Localization of Sigma-2 Receptors in Breast Cancer Cells Using Two-Photon and Confocal Microscopy. Cancer Research, 2007, 67, 6708-6716.	0.9	112
65	IN VIVO IMAGING IN A MURINE MODEL OF GLIOBLASTOMA. Neurosurgery, 2007, 60, 360-371.	1.1	37
66	Fluorine-18-Labeled Benzamide Analogues for Imaging the Ïf2 Receptor Status of Solid Tumors with Positron Emission Tomography. Journal of Medicinal Chemistry, 2007, 50, 3194-3204.	6.4	102
67	Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Molecular Cancer, 2007, 6, 48.	19.2	118
68	Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl carbamate analogs as σ2 receptor ligands. Bioorganic and Medicinal Chemistry, 2006, 14, 6988-6997.	3.0	45
69	Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5041-5046.	2.2	116
70	Synthesis and characterization of selective dopamine D2 receptor antagonists. Bioorganic and Medicinal Chemistry, 2006, 14, 815-825.	3.0	36
71	Synthesis and in vivo evaluation of 2 high-affinity 76Br-labeled sigma2-receptor ligands. Journal of Nuclear Medicine, 2006, 47, 1041-8.	5.0	37
72	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorganic and Medicinal Chemistry, 2005, 13, 77-87.	3.0	99

#	Article	IF	CITATIONS
73	[3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: A novel sigma-2 receptor probe. European Journal of Pharmacology, 2005, 525, 8-17.	3.5	60
74	A Modified Micropipette Aspiration Technique and Its Application to Tether Formation From Human Neutrophils. Journal of Biomechanical Engineering, 2002, 124, 388-396.	1.3	53
75	The Striatal DNA Damage and Neurodegenerations. , 0, , .		0